Introduction
============

In recent years, the mortality rate for colorectal cancer is over 600,000 patients annually ([@b1-ol-0-0-4843]). Early discovery, diagnosis and treatment are imperative for patients with colorectal cancer. The occurrence of colorectal cancer is the result of combined actions of multiple genes, factors and steps. Epigenetic change is a type of abnormal gene expression without the occurrence of gene sequence changes, including histone markers and gene methylation. Gene methylation is an early tumor event, and the process is reversible, which provides theoretical evidence for methylation-relevant gene application and clinical early diagnosis and treatment ([@b2-ol-0-0-4843],[@b3-ol-0-0-4843]).

*PAQR3* is a cancer suppressor gene and is involved in various signal channels that can influence biological processes such as energy metabolism, cell proliferation, differentiation and the maturity of reproductive cells, and can negatively regulate the Ras/Raf/MEK/ERK signal channel ([@b4-ol-0-0-4843]). In experiments in nude mice with colorectal cancer, it was verified that PAQR3 plays a role in cancer inhibition in colorectal cancer tissues, and the deficiency of PAQR3 expression reduced the survival time of gene-knockout nude mice ([@b4-ol-0-0-4843]). In addition, a low expression of PAQR3 in tumor tissues of gastric cancer, breast cancer, melanoma and liver cancer has been demonstrated. PAQR3 was able to enhance the sensitivity of breast cancer SK-BR-3 cells to epirubicin ([@b5-ol-0-0-4843]--[@b13-ol-0-0-4843]). However, studies should be performed on cancer suppressor gene *PAQR3* mRNA and protein levels of colorectal cancer to assist in the diagnosis and treatment of colorectal cancer.

PAQR3 is a member of the progesterone and adiponectin receptor (PAQR) family, which plays a role in cancer inhibition in colorectal cancer cells, and is involved in biological processes such as signal transduction, energy metabolism, cell proliferation, differentiation and the maturity of reproductive cells. The purpose of adjusting physiological processes such as proliferation, differentiation, apoptosis, malignant transformation of cells and the occurrence and development of cancer is reached through the negative regulation of the Ras/Raf/MEK/ERK signal channel ([@b5-ol-0-0-4843]--[@b9-ol-0-0-4843]). In addition, the AKT signal channel is negatively regulated by PAQR3 through two mechanisms. After knockout of PAQR3, the expression of p110α in the cytoplast in combination with the dictyosome is decreased, PAQR3 combined and changed the subcellular localization of p110α of PI3K of compounds in the cytoplast, and prevented the combination with the p85 control site, resulting in the inactivation of PI3K and the phosphorylation of AKT, a process that influences the signal channel of insulin. By contrast, PAQR3 is able to block the Gβ locus of GPCR, and inhibits the function of AKT in GRCR-activated Gβ/γ locus. In gastric cancer tissues, PAQR3 negatively regulates the phosphorylation of ERK and AKT, which demonstrates that PAQR3 plays a role in the process of negatively regulating EMT through inhibition of the ERK and AKT signal channel ([@b10-ol-0-0-4843]--[@b13-ol-0-0-4843]). As the cancer suppressor gene in colorectal cancer, the silencing mechanism of *PAQR3* remains to be determined.

The aim of the present study was to investigate *PAQR3* gene expression and its methylation level in colorectal cancer tissues, as well as the association with colorectal cancer clinical data. The results of the present study provide theoretical evidence for the diagnosis and treatment of colorectal cancer.

Patients and methods
====================

### Tissue extraction

In total, 54 pairs of colorectal cancer and normal tissues, respectively, were collected from the Department of General Surgery of the Affiliated Hospital of Hebei University, between June, 2013 and July, 2014. Inclusion criteria for the study were that, the patients did not receive radiotherapy, chemotherapy or immunotherapy prior to surgery. Any tumor tissues that had already necrosis on collection of cancer tissue samples, were excluded. Normal tissues that were \>10 cm from the edge of cancer tissue were collected as the cancer adjacent normal tissues. Full-thickness of the tissue was selected, and the diagnostic results were confirmed by the postoperative pathological results. There were 32 male and 22 female patients, 19 patients with rectal cancer and 35 patients with colon cancer, with an age range of 36--82 years and an average age of 59.69 years. The samples were collected during surgery, placed in liquid nitrogen, and preserved at −80°C for ≤6 months.

### Reagents

The Omega E.Z.N.A.™ overall RNA extraction kit, Vazyme HiScript First Strand cDNA synthesis kit, RT-qPCR fluorescence quantitation kit, Qiagen EpiTect Fast DNA Bisulfite kit, proteinase K, RNaseA, RNA enzyme EP tubes, PAQR3 and β-actin antibodies were all purchased from Shijiazhuang Huiyou Biological Technology Co., Ltd. (Shijiazhuang, China). β-actin, PAQR3, PAQR3 methylation and non-methylation primers were synthesized according to the design of Primer Premier 5.0 software, their specificities were detected through PubMed Blast, and all the primers were produced by Sangon Biotech Co. Ltd. (Shanghai, China). STE lysate, SDS, agarose, chloroform, isoamyl, absolute ethanol, 75% absolute ethanol, Tris-phenol, phenol/chloroform/isoamylol (25:24:1), chloroform/isoamylol (24:1). TE buffer solution and anhydrous sodium acetate were used in the process of DNA extraction and nucleic acid electrophoresis. Protein lysis buffer, PMSF, 1X PBS, and 5X loading buffer were used for protein isolation. Gel electrophoresis, separation gel and running buffer, methanol, and 1X transfer membrane buffer were used for western blot analysis. Coomassie blue staining solution, and Coomassie brilliant blue bleaching liquid were used for quantification of the isolated proteins. PVDF membrane was used for immunoblotting. The membrane was incubated in primary antibody, and the secondary antibody was added in 5% skim milk in TBST. Materials for western blot analysis were provided by the Central Laboratory of the Affiliated Hospital of Hebei University.

### Quantitative RT-PCR

#### Tissue RNA extraction

Tissue (30 mg) was collected and RNA was extracted according to the instructions of the Omega E.Z.N.A.™ RNA extraction kit. Product (2 µl) was collected for separation on 1% sepharose gel for electrophoresis. Reverse transcription was carried out after the ELISA test, and the content (2,000 ng/µl) and ratio (OD: 1.9--2.0) were determined.

#### Reverse transcription

RNA content was adjusted according to RNA quantitative results. RNA (1 µg) was collected, and reverse transcription was carried out according to the instructions of the Vazyme HiScript First Strand cDNA synthesis kit. The reaction conditions were denaturation at 25°C for 5 min, annealing at 42°C for 30 min, and elongation at 85°C for 5 min.

#### PCR

PCR primers were designed using Primer Premier 5.0. The reference gene was β-*actin* primer: 5′-GTGGACATCCGCAAAGAC-3′ (F), 5′-AAAGGGTGTAACGCAACTAA-3′ (R), and the length of the product was 302 bp. The PDCD4 primer was 5′-TGGGAGTGACGCCCTTAGAA-3′ (F), 5′-TCCACCTCCTCCACATCATACA-3′ (R), and the length of the product was 171 bp. The PAQR3 primer was 5′-TCTGTATGCTTTGCTCTGTGGG-3′ (F), 5′-TTTGCCATTGCTGCGTGAG-3′ (R), and the length of the product was 252 bp. The reaction conditions were 95°C for 5 min, 95°C for 10 sec, 60°C for 32 sec, for 40 cycles; and 95°C for 15 sec, 60°C for 60 sec, 95°C for 15 sec. The results were normalized to β-actin.

#### Western blot analysis

Protein expression levels in tissues were analyzed using western blot analysis as previously described ([@b14-ol-0-0-4843]). The membranes were incubated with primary goat antibody in a dilution of 1:500 (anti-PAQR3; cat. no. sc-161992; Santa Cruz Biotechnology, Santa Cruz, CA, USA) overnight at 4°C. The membrane was washed with TBST and incubated with a peroxidase-conjugated secondary polyclonal rabbit-anti-goat antibody (dilution: 1:1,000; cat. no. sc-2768; Santa Cruz Biotechnology) for 1 h. Western blot film was scanned and the membrane was stripped and reprobed with antibody against β-actin (dilution: 1:1,500) to confirm equal sample loading.

#### Methylation-specific PCR (MSP)

The phenol/chloroform extraction method was used to extract tissue DNA. Hydrosulphite modification was then performed according to the instructions on the EpiTect Fast DNA Bisulfite kit. PAQR3 methylation and non-methylation primers were designed and produced using MethPrimer software (Sangon Biotech Co., Ltd.).

The PAQR3 methylation primer was: (M) 5′-TTGTTGAAGAGCGCGTATTATATC-3′ (F), 5′-TAAAAACCCGAAAATCTACTCGTA-3′ (R), and non-methylation primer was: (U) 5′-TTGTTGAAGAGTGTGTATTATATTGA-3′ (F), 5′-TAAAAAACCCAAAAATCTACTCATA-3′ (R). The PAQR4 methylation primer was: (M) 5′-TTTAGTTTCGGTTTCGTCGTTAC-3′ (F), 5′-GAAAAATCTCTAACCCTTCTCGC-3′ (R), and non-methylation primer was: (U) 5′-TTTAGTTTTGGTTTTGTTGTTATGA-3′ (F), 5′-CAAAAAATCTCTAACCCTTCTCACT-3′ (R). The reference gene β-actin primer was: 5′-GTGGACATCCGCAAAGAC-3′ (F), 5′-AAAGGGTGTAACGCAACTAA-3′ (R).

#### Statistical analysis

Data were analysed using statistical software SPSS 16.0 (Chicago, IL, USA). The χ^2^ test and Spearman relevant analysis, and two-tailed test were used for comparisons between groups. P\<0.05 was considered statistically significant.

Results
=======

### PAQR3 mRNA level in colorectal cancer tissues

The PAQR3 mRNA expression level in colorectal cancer tissues was markedly reduced and the expression reduction rate was 57.4% (31/54), with PAQR3 mRNA in cancer tissues being 9.321.97, while that of normal adjacent tissues was 8.442.42. The difference was of statistical significance (P=0.001) ([Fig. 1](#f1-ol-0-0-4843){ref-type="fig"}).

### PAQR3 protein level in colorectal cancer tissues

The expression level of PAQR3 protein was significantly low, the protein expression reduction rate in cancer tissue was 46.3% (25/54), while the protein expression reduction rate in cancer adjacent tissue was 5.6% (3/54). The difference was of statistical significance (P\<0.05) ([Fig. 2](#f2-ol-0-0-4843){ref-type="fig"}).

### PAQR3 gene methylation level in colorectal cancer tissues

Methylation rates of PAQR3 in cancer tissues and cancer adjacent tissues were 33.3% (18/54) and 5.6% (3/54), respectively. The methylation rate of PAQR3 in cancer tissues was significantly higher than that in the corresponding normal cancer adjacent tissues (P\<0.05) ([Fig. 3](#f3-ol-0-0-4843){ref-type="fig"}).

### Association of the PAQR3 mRNA and protein levels and colorectal cancer clinical parameters

Statistical software was detected using the Fisher\'s exact test probability method. The PAQR3 mRNA and protein levels were not correlated with gender, age or tumor location, but were statistically significant for differentiation degree, lymphatic metastasis and tumor infiltration depth ([Table I](#tI-ol-0-0-4843){ref-type="table"}).

### Association between PDCD4 gene methylation and colorectal cancer clinical data

The methylation level of *PAQR3* gene in colorectal cancer tissues was not correlated with gender or tumor location, but was associated with age, differentiation degree, lymphatic metastasis and tumor infiltration depth. The higher the age of the patient, the lower the differentiation degree observed, and the deeper the lymphatic metastasis and tumor infiltration the higher the methylation rate found, and vice versa ([Table II](#tII-ol-0-0-4843){ref-type="table"}).

Discussion
==========

The function of the *PAQR3* gene and it inhibitory role in colorectal cancer was identified by Chen and Xie in 2009 ([@b5-ol-0-0-4843]). The gene is involved in various signal channels of cells, which can influence biological processes such as energy metabolism, cell proliferation, differentiation and the mature reproductive cells. It is also known as PKTG, which can encode 7-fold transmembrane protein of 37 kDa, N-end towards cytoplasm, C-end towards organelle, and is situated at the Golgi membrane, which can negatively regulate the Ras/Raf/MEK/ERK signal channel. This signal channel is one of the typical routes of the crystal-induced mitogen-activated protein kinase cascade signal. The PAQR3 protein competitively binds to RAF, and disturbs the combination between RAF and the downstream signal molecule substrate, which is used to identify extracellular signals and transfer extracellular stimulating signals into cells. This can achieve the purpose of physiological processes such as regulating cell proliferation, differentiation, apoptosis and malignant transformation of cells, as well as the occurrence and development of cancer ([@b5-ol-0-0-4843]--[@b9-ol-0-0-4843]). Wang *et al* also verified that PAQR3 plays a role in cancer inhibition in colorectal cancer tissues, and the deficiency of PAQR3 expression reduces the survival time of gene-knockout nude mice ([@b15-ol-0-0-4843]). In the study on human melanoma A375, the overexpression of PAQR3 clearly inhibited the amplification and malignant transformation of cells, and in the nude mouse transplantation tumor experiment, the re-expression of PAQR3 through siRNA clearly inhibited the effects of subcutaneous tumors, and the stimulation of abnormally activated ERK downstream was inhibited ([@b16-ol-0-0-4843]). In addition, the expression of PAQR3 in tumor tissues, such as breast cancer, was reduced, and PAQR3 enhanced the sensitivity of breast cancer SK-BR-3 cells to epirubicin ([@b17-ol-0-0-4843]).

The silencing mechanism of PAQR3 is not clear, thus, the gene promoter mRNA and protein levels in colorectal cancer tissues were detected to determine their association. In the present study, through the detection of tissue samples of 54 pairs of patients with colorectal cancer, it was verified that the expression of PAQR3 in colorectal cancer is reduced, and this shows that PAQR3 mRNA and protein levels in colorectal cancer tissues was not associated with gender, age or tumor location, but were correlated with differentiation degree, lymphatic metastasis and tumor infiltration depth. Previous studies only mentioned that the expression level of PAQR3 protein was reduced; however, the association between the reduction rate of protein expression and clinical data in colorectal cancer tissues was not clear ([@b12-ol-0-0-4843],[@b15-ol-0-0-4843]). Due to the limitation of the number of samples, this result was not completely consistent.

Wang *et al* detected that the reduction rate of PAQR3 mRNA expression in colorectal cancer was 82.3% (51/62), which is different from our results of 57.4% (31/54) ([@b18-ol-0-0-4843]). However, compared with normal cancer adjacent tissues, statistical significance was observed. Authors of that study mentioned that the reduction rate of PAQR3 mRNA expression was higher in male compared to female patients, which is consistent with the epidemiological analysis results that male patients have higher morbidity in colorectal cancer compared to female patients ([@b19-ol-0-0-4843]). In the present study, there were more male samples collected than female samples. However, the results showed that, the reduction of PAQR3 expression was not associated with gender, which was a result based on sample and regional difference. In addition, Wang *et al* found that the PAQR3 mRNA level in colorectal cancer tissues was not associated with tumor location or age, which is consistent with the results of the present study. However, its relationship with tumor differentiation degree was not analyzed. In the present study, the PAQR3 mRNA level was relevant to lymphatic metastasis, tumor infiltration depth and tumor differentiation degree, and this was considered to be relevant to the number of samples collected. These indexes can be used as prognosis monitoring indicators of patients and remain to be confirmed by clinical follow-up research.

Through the detection of the methylation level of *PAQR3* gene in colorectal cancer tissues, the present study evaluated methylation in colorectal cancer, and its association with clinical data. Gene methylation is an early event of tumorigenesis that can be used as diagnostic evidence of colorectal cancer. The methylation rate of PAQR3 was 33.3% (18/54), which was of statistical significance, compared to the methylation level of the normal cancer adjacent tissues. To the best of our knowledge, there are currently no studies on *PAQR3* gene methylation, and the results of our study verified that *PAQR3* gene methylation is involved in the formation of colorectal cancer, and can be used as the tumor marker thereof. At the same time we found that PAQR3 methylation level was relevant to age; thus, the older the patient was, the higher the *PAQR3* gene methylation rate. The analysis of the relevance between gene methylation and age shows that, with the increase of age, methylation of the organism was higher. The age-relevant methylation level changing mechanism remains to be clarified, and this relationship has received controversion results from different research groups. First of all, with increasing age, enzymatic activity in the human body is altered, promoting gene methylation. This may be influenced by geographical environmental elements, random selection and sample size, although this difference was not statistically significant ([@b20-ol-0-0-4843]). The high methylation level of *PAQR3* gene is associated with differentiated degree, lymphatic metastasis and tumor infiltration depth. Concerning gene methylation is the early event of tumorigenesis ([@b21-ol-0-0-4843]), the lower the differentiated degree the higher the gene methylation level was, and at a low gene expression level the ability of cancer inhibition was minimal. With the increase of differentiation degree, the possibility of methylation occurrence was less. Therefore, the lower the differentiation degree was in tumor tissues, the higher the possibility of gene methylation. PAQR3 methylation was relevant to tumor infiltration depth of colorectal cancer and lymphatic metastasis, and considering the consequence of *PAQR3* gene silencing, PAQR3 can be used as the monitoring prognostic indicator of colorectal cancer. The present results verified the role that *PAQR3* gene methylation plays in colorectal cancer, which provides effective theoretical evidences for further *in vitro* experiments, reverse gene methylation and re-expression of cancer suppressor genes.

###### 

RT-qPCR for PAQR3 mRNA expression level for normal and cancer cells. (A) Trend for Rn (fluorescence signal) vs. cycle number for colorectal cancer and normal adjacent tissues. (B) Agarose gel electrophoresis for actin (302 bp), PCD4 (171 bp), and PAQR3 (252 bp) PCR product. C, colorectal cancer tissues; N, normal cancer adjacent tissues.
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![PAQR3 protein expression condition.](ol-12-03-1773-g02){#f2-ol-0-0-4843}

![Agarose gel electrophoresis for the amplified products of PAQR3 MSP in colorectal cancer tissues. Marker, marker β-actin as internal reference; C, colorectal cancer tissues; N, normal cancer adjacent tissues; M, methylation primer; N, non-methylation primer; MSP, methylation-specific PCR.](ol-12-03-1773-g03){#f3-ol-0-0-4843}

###### 

Association of the PAQR3 mRNA and protein levels and colorectal cancer clinical parameters.

                          Colorectal cancer tissues                                                                                  
  ----------------------- --------------------------- ----- ------ ---------------------------------------------------- ----- ------ ----------------------------------------------------
  Gender                                                                                                                             
    Male                  32                          18    56.2   0.836                                                15    46.9   0.059
                                                        9                                                                 9          
    Female                22                          13    59.1                                                        16           
                                                        4                                                                 4   72.7   
  Age (years)                                                                                                                        
    \<60                  29                          17    68.0   0.144                                                19    65.5   0.194
                                                        8                                                                            
    ≥60                   25                          14    48.3                                                        12    48.0   
                                                        5                                                                 5          
  Location                                                                                                                           
    Colon                 35                          19    54.3   0.529                                                23    65.7   0.094
                                                        6                                                                 6          
    Rectum                19                          12    63.2                                                          8   42.1   
                                                        7                                                                 7          
  Differentiated degree                                                                                                              
    Level I--II           30                          12    40.0   0.004^[a](#tfn1-ol-0-0-4843){ref-type="table-fn"}^   11    36.7   0.001^[a](#tfn1-ol-0-0-4843){ref-type="table-fn"}^
                                                        9                                                                 9          
    Level III             24                          19    79.2                                                                     
                                                        4                                                               20    83.3   
  Lymphatic metastasis                                                                                                               
    No                    28                          11    39.3   0.005^[a](#tfn1-ol-0-0-4843){ref-type="table-fn"}^   12    42.9   0.025^[a](#tfn1-ol-0-0-4843){ref-type="table-fn"}^
                                                        9                                                                 9          
    Yes                   26                          20    76.9                                                        19    73.1   
                                                        4                                                                            
  Depth of infiltration                                                                                                              
    Muscularis mucosae    31                          14    45.2   0.035^[a](#tfn1-ol-0-0-4843){ref-type="table-fn"}^   13    41.9   0.008^[a](#tfn1-ol-0-0-4843){ref-type="table-fn"}^
    Around serosa         23                          17    73.9                                                        18    78.3   

Significant differences.

###### 

Association between *PDCD4* gene methylation level and colorectal cancer clinical data.

                          Colorectal cancer tissues                
  ----------------------- --------------------------- ----- ------ ----------------------------------------------------
  Gender                                                           
    Male                  32                          11    34.4   0.845
    Female                22                            7   31.8   
  Age (years)                                                      
    \<60                  29                            6   20.7   0.034^[a](#tfn2-ol-0-0-4843){ref-type="table-fn"}^
    ≥60                   25                          12    48.0   
  Location                                                         
    Colon                 35                          10    28.6   0.314
    Rectum                19                            8   42.1   
  Differentiated degree                                            
    Level I--II           30                          15    50.0   0.004^[b](#tfn3-ol-0-0-4843){ref-type="table-fn"}^
    Level III             24                            3   12.5   
  Lymphatic metastasis                                             
    No                    28                            4   14.3   0.036^[a](#tfn2-ol-0-0-4843){ref-type="table-fn"}^
    Yes                   26                          14    53.8   
  Depth of infiltration                                            
    Muscularis mucosae    31                          14    45.2   0.032^[a](#tfn2-ol-0-0-4843){ref-type="table-fn"}^
    Around serosa         23                            4   17.4   

Represents differences

represents significant differences.
